

Our PureActives® are manufactured using our patented enzymatic platform. This enzymatic platform completely replaces the traditional 13-step antibiotic production process with natural processes that eliminate the use of solvents or other chemicals.

We take pride in knowing that our PureActives® are the world's purest and most environmentally friendly produced APIs and FDFs.

## Active Pharmaceutical Ingredients Portfolio

Class	Product name	Grade	Status
Antifungals	Nystatin	Powder	Available
		Micronized	Available
		Mycelium	Available
Betalactam Intermediates 	6-APA (6-Amino Penicillanic Acid)	-	Available
	7-ADCA (7-Amino Deacetoxy Cephalosporanic Acid)	-	Available
Isoxazoles	Cloxacillin Sodium	Compacted	Available
		Powder	Available
	Dicloxacillin Sodium	Compacted	Available
		Compacted	Available
Penicillin G	Penicillin G Potassium	-	Available
	Penicillin G Procaine	-	Available
	Penicillin G Procaine	Sterile	To be commercialized / samples available
	Penicillin G Benzathine	Sterile	To be commercialized / samples available
Semi-Synthetic Cephalosporins 	Purilex® - Cefalexin Monohydrate	Compacted	Available
		Powder	Available
	Puridrox® - Cefadroxil Monohydrate	Compacted	Available
		Powder	Available
	Puridin® - Cefradine	Compacted	Available
		Powder	Available
	Puriclor® - Cefaclor	Powder	Available
		Powder	Available
Semi-Synthetic Penicillins 	Purimox® - Amoxicillin Trihydrate	Powder Extra Dry	Available
		Compacted	Available
		Compacted Extra Dry	Available
		Micronized	Available
	Puricillin® - Ampicillin Trihydrate	Other Special	Available
		Powder	Available
		Compacted	Available
		Other Special	Available
		Micronized	Available
		Non-Micronized	Available
Statins	Atorvastatin Calcium Trihydrate	Micronized	Available
	Rosuvastatin Calcium	Micronized	Available
Betalactamase Inhibitor	Avibactam	-	Under development
	Clavulanic Acid	-	Under development
	Tazobactam	-	Under development
Betalactam + Inhibitor	Piperacillin / Tazobactam	Sterile mix 8:1	Under development
Diabetes	Dapagliflozin	-	Under development
	Empagliflozin	-	Under development
	Sitagliptin Phosphate	-	Under development
Gastrointestinal	Ursodeoxycholic Acid	-	Under development















\*Under development list are non-exhaustive

## Distribution Portfolio

Class	Product name	Grade	Status
Cardiovascular	Irbersartan	-	Available
	Metoprolol Tartrate	-	Available
Central Nervous System	Quetiapine Fumarate	-	Available
Anti-infectives for systemic use	Clindamycin Phosphate	-	Under consideration
	Clindamycin Hydrochloride	-	Under consideration
Central Nervous System	Lacosamide	-	Under consideration

Under consideration list are non-exhaustive

## Finished Dosage Forms Portfolio

Class	Product name	Dosage form	Strength	Status*
Betalactam Antibiotic	Amoxicillin 	 Hard capsule	500 mg	EU - CTD
		 Tablet (Dispersible)	500 mg	EU - CTD
			750 mg	
			1,000 mg	
		 Powder for oral suspension	125 mg/5 ml	EU - CTD
			250 mg/5 ml	
	500 mg/5 ml			
	Amoxicillin + Clavulanic Acid	 Film-coated tablet	500 mg+125 mg (4:1)	EU - CTD, Zone IV
			875 mg+125 mg (7:1)	
			500 mg+62.5 mg (8:1)	
		 Powder for oral suspension	400 mg+57 mg (7:1) /5ml	EU - CTD, Zone IV
			600 mg+42.9 mg (14:1) /5ml	
			500 mg+62.5 mg (8:1) /5ml	
		 Powder for oral suspension in sachet	500 mg+125 mg (4:1)	EU - CTD
			875 mg+125 mg (7:1)	
1,000 mg+125 mg (8:1)				
Statins	Atorvastatin	 Film-coated tablet	10 mg, 20 mg, 40 mg, 80 mg	EU - CTD, Zone IV
			30mg, 60mg	EU - CTD
	Rosuvastatin	 Film-coated tablet	5 mg, 10 mg, 20 mg, 40 mg	EU - CTD, Zone IV
Antifungals	Caspofungin	 Powder for concentrate for solution for infusion	50 mg, 70 mg	Under development
Antibiotics	Amoxicillin + Clavulanic Acid	 Dispersible Tablets	400/57, 500/125 mg, 875/125 mg	Under consideration
	Dalbavancin Hydrochloride	 Powder for concentrate for solution for infusion	500 mg	Under development
	Fidaxomicin	 Film-coated tablet	200 mg	Under development
	Rifaximin	 Film-coated tablet	200 mg, 400 mg, 550 mg	Under consideration

Under development and Under consideration list are non-exhaustive.

\*All dossiers available for world-wide filing. Availability of dossiers is dependent on local regulatory requirements.

The information contained here is provided to best of CENTRIENT's knowledge, for evaluation purposes only, and should not be construed as an offer for sale. CENTRIENT makes nor representations and provides no warranties of any kind in this document, including in connection with the completeness of the information provided in it, the patentability of the products mentioned in it or the existence of freedom-to-operate in any given countries.

It is of paramount importance to CENTRIENT to respect the intellectual property rights of third-parties, therefore the products included in this brochure shall not be used in jurisdictions where incompatible and valid third-party rights may be in force; in the case of such jurisdictions said products are only presented in this document to be evaluated for regulatory purposes only, and provided these are allowed under local provisions, such as the "Bolar" provisions in the U.S. and the EU Directive No. 2004/27/EC.



For further information about who we are and what we do, please visit [www.centrient.com](http://www.centrient.com), or email us at: [info@centrient.com](mailto:info@centrient.com).

Follow us on LinkedIn: <https://www.linkedin.com/company/centrient>

Headquarters address: First Building, 2<sup>4</sup>th floor, Weena 798 E-F, 3014 DA Rotterdam, The Netherlands

Copyright © 2025 Centrient Pharmaceuticals. All rights reserved.

Although all reasonable and diligent care has been used to ensure that the information provided herein is accurate, nothing contained herein shall, or may, be construed to imply any representation or warranty as to the accuracy, currency or completeness of this information nor shall it be construed to imply any other representation or warranty of any kind, including the implied warranties of merchantability, fitness for a particular purpose or non-infringement. Centrient has no obligation to update the statements contained in this presentation, unless required by applicable law. The content of this document is subject to change without any notice. Product offers are explicitly not made in respect of those jurisdictions where valid third party patent rights related to such products are in force. In such jurisdictions the advertised products are only offered for regulatory purposes insofar allowed under local provisions such as the Bolar provisions in the US and 2004/27/EC in Europe. V05032025